Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy

Eric Robach, Celaletin Ustun, Andre Kallab, Russel E. Burgess, Anand P. Jillella

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.

Original languageEnglish (US)
Pages (from-to)2235-2236
Number of pages2
JournalLeukemia and Lymphoma
Volume43
Issue number11
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Keywords

  • Diffuse large B-cell lymphoma
  • Lymphoma
  • Rituxan
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy'. Together they form a unique fingerprint.

  • Cite this